{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023110","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.564643+00:00","generated_at":"2026-05-17T14:54:13.121836+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MIRA's Ketamir-2 manuscript accepted for publication; shows superior efficacy in neuropathic pain models","bullets":["Ketamir-2 manuscript accepted in Frontiers in Pharmacology; outperformed ketamine, pregabalin, gabapentin in preclinical models.","Restored sensory function and reversed pain behaviors across genders and species in two validated models.","Global neuropathic pain market: $7.97B (2024) projected to $16.79B by 2034, CAGR 7.73%; North America ~$3.7-3.9B.","Company plans to submit Phase 2a protocol to FDA in Q4 2025, aiming to initiate study by year-end.","Also evaluating Ketamir-2 for depression, anxiety, PTSD, and as a topical formulation for localized pain."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023110","json":"https://secwatch.observer/filing/0001641172-25-023110.json","markdown":"https://secwatch.observer/filing/0001641172-25-023110.md","text":"https://secwatch.observer/filing/0001641172-25-023110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225023110/0001641172-25-023110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225023110/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:54:13.121836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}